Published online Aug 8, 2021. doi: 10.5320/wjr.v11.i1.12
Peer-review started: March 7, 2021
First decision: May 6, 2021
Revised: May 17, 2021
Accepted: July 14, 2021
Article in press: July 14, 2021
Published online: August 8, 2021
Venous thromboembolism, which includes deep venous thrombosis and pulmonary embolism, is a well-known causal disorder with high morbidity and mortality rates. Inherited or acquired conditions affecting components of coagulation and fibrinolysis systems have been linked to venous thromboembolism pathogenesis as they may lead to a pro-inflammatory state in human bodies. Toxoplasmosis is a zoonosis that potentially leads to acute systemic cachectic-inflammatory effects in experimental animal models but is not yet proven in humans. It is known that venous thrombosis can occur during acute inflammatory/infectious diseases, although it is not well established with regard to toxoplasmosis alone.
A 70-year-old Caucasian man and his 32-year-old son developed general malaise, chills, fever, and myalgia, having established a diagnosis of toxoplasmosis. Twenty days later, they presented dry cough leading to further investigations that revealed an incidental deep venous thrombosis plus pulmonary embolism in them both. Thrombophilia screening showed both patients had a factor V Leiden mutation heterozygosis. Father and son completely recovered without any sequalae after anticoagulant treatment. They have not presented symptom recurrence of either medical disorder during 1 year of follow-up.
Toxoplasmosis may enhance the risk of venous thromboembolism in patients showing factor V Leiden mutation heterozygosis.
Core Tip: This paper describes two closely related patients simultaneously infected by Toxoplasma gondii who concurrently presented their first venous thromboembolism episode. Further investigation revealed a factor V Leiden mutation in them both. The association between these two morbid conditions suggests that systemic infection/ inflammation may enhance the risk of venous thromboembolism in people carrying this kind of pro-thrombophilia mutation. As far as we know, this is the first report of that association. We believe that this paper provides an insight into this important issue bringing potential help for clinical decision-making processes by doctors around the world.